Targeting Sphingosine Kinases for the Treatment of Cancer

Clayton S. Lewis, Christina Voelkel-Johnson, Charles D. Smith

Research output: Chapter in Book/Report/Conference proceedingChapter

14 Scopus citations

Abstract

Sphingosine kinases (SK1 and SK2) are key, druggable targets within the sphingolipid metabolism pathway that promote tumor growth and pathologic inflammation. A variety of isozyme-selective and dual inhibitors of SK1 and SK2 have been described in the literature, and at least one compound has reached clinical testing in cancer patients. In this chapter, we will review the rationale for targeting SKs and summarize the preclinical and emerging clinical data for ABC294640 as the first-in-class selective inhibitor of SK2.

Original languageEnglish (US)
Title of host publicationAdvances in Cancer Research
EditorsCharles E. Chalfant, Paul B. Fisher
PublisherAcademic Press Inc.
Pages295-325
Number of pages31
ISBN (Print)9780128142233
DOIs
StatePublished - Jan 1 2018

Publication series

NameAdvances in Cancer Research
Volume140
ISSN (Print)0065-230X
ISSN (Electronic)2162-5557

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting Sphingosine Kinases for the Treatment of Cancer'. Together they form a unique fingerprint.

Cite this